Increased risk of periodontitis among patients with Crohn’s disease

a population-based matched-cohort study

Ying Chen Chi, Jiunn Liang Chen, Li Hsuan Wang, Koyin Chang, Chen Long Wu, Shu Yi Lin, Joseph Jordan Keller, Chyi Huey Bai

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Background: Periodontitis is a frequently cited extraintestinal manifestation of Crohn’s disease (CD). Despite a plethora of investigations and a recent meta-analysis linking CD and periodontitis, no study has estimated the risk of periodontitis among CD patients with respect to a comparison group nor has any investigation analyzed the effect of CD-specific medications on the risk of periodontitis. The present cohort study compared CD patients and matched subjects without a history of inflammatory bowel disease (IBD) to estimate the effect of CD and CD-specific pharmaceutical prescriptions on the risk of developing periodontitis by leveraging a population-based dataset in Taiwan. Methods: We sourced 6657 CD patients and 26,628 comparison subjects without a history of IBD from the Taiwan National Health Insurance Database. Cox proportional hazards regressions were used to estimate the risk of subsequent periodontitis by CD status and pharmaceutical prescription during the follow-up period. Results: After adjusting for socioeconomic status (SES), urbanicity, selected medical co-morbidities, and CD-specific pharmaceutical prescriptions, the hazard ratio (HR) for subsequent periodontitis among patients with CD was 1.36 (95% CI = 1.25–1.48) that of comparison subjects. There was not a significant difference in risk between genders or across ages. Steroids (95% CI = 0.66–0.77) appeared to confer a protective effect and Aspirin, Plavix, and Licodin were marginally protective (95% CI = 0.76–0.95). Conclusion: This is the first study to report an increased HR for subsequent periodontitis among CD patients when compared to matched comparison subjects without IBD. The protective effect of some pharmaceuticals may suggest that treatment of CD protects against periodontitis.
原文英語
頁(從 - 到)1437-1444
頁數8
期刊International Journal of Colorectal Disease
33
發行號10
DOIs
出版狀態已發佈 - 十月 1 2018

指紋

Periodontitis
Crohn Disease
Cohort Studies
Population
Inflammatory Bowel Diseases
Prescriptions
clopidogrel
Taiwan
Pharmaceutical Preparations
National Health Programs
Social Class
Aspirin
Meta-Analysis
Steroids

ASJC Scopus subject areas

  • Gastroenterology

引用此文

Increased risk of periodontitis among patients with Crohn’s disease : a population-based matched-cohort study. / Chi, Ying Chen; Chen, Jiunn Liang; Wang, Li Hsuan; Chang, Koyin; Wu, Chen Long; Lin, Shu Yi; Keller, Joseph Jordan; Bai, Chyi Huey.

於: International Journal of Colorectal Disease, 卷 33, 編號 10, 01.10.2018, p. 1437-1444.

研究成果: 雜誌貢獻文章

Chi, Ying Chen ; Chen, Jiunn Liang ; Wang, Li Hsuan ; Chang, Koyin ; Wu, Chen Long ; Lin, Shu Yi ; Keller, Joseph Jordan ; Bai, Chyi Huey. / Increased risk of periodontitis among patients with Crohn’s disease : a population-based matched-cohort study. 於: International Journal of Colorectal Disease. 2018 ; 卷 33, 編號 10. 頁 1437-1444.
@article{59fdb0c2e5254e8983055f1949a05e9d,
title = "Increased risk of periodontitis among patients with Crohn’s disease: a population-based matched-cohort study",
abstract = "Background: Periodontitis is a frequently cited extraintestinal manifestation of Crohn’s disease (CD). Despite a plethora of investigations and a recent meta-analysis linking CD and periodontitis, no study has estimated the risk of periodontitis among CD patients with respect to a comparison group nor has any investigation analyzed the effect of CD-specific medications on the risk of periodontitis. The present cohort study compared CD patients and matched subjects without a history of inflammatory bowel disease (IBD) to estimate the effect of CD and CD-specific pharmaceutical prescriptions on the risk of developing periodontitis by leveraging a population-based dataset in Taiwan. Methods: We sourced 6657 CD patients and 26,628 comparison subjects without a history of IBD from the Taiwan National Health Insurance Database. Cox proportional hazards regressions were used to estimate the risk of subsequent periodontitis by CD status and pharmaceutical prescription during the follow-up period. Results: After adjusting for socioeconomic status (SES), urbanicity, selected medical co-morbidities, and CD-specific pharmaceutical prescriptions, the hazard ratio (HR) for subsequent periodontitis among patients with CD was 1.36 (95{\%} CI = 1.25–1.48) that of comparison subjects. There was not a significant difference in risk between genders or across ages. Steroids (95{\%} CI = 0.66–0.77) appeared to confer a protective effect and Aspirin, Plavix, and Licodin were marginally protective (95{\%} CI = 0.76–0.95). Conclusion: This is the first study to report an increased HR for subsequent periodontitis among CD patients when compared to matched comparison subjects without IBD. The protective effect of some pharmaceuticals may suggest that treatment of CD protects against periodontitis.",
keywords = "Crohn’s disease, Epidemiology, Periodontitis",
author = "Chi, {Ying Chen} and Chen, {Jiunn Liang} and Wang, {Li Hsuan} and Koyin Chang and Wu, {Chen Long} and Lin, {Shu Yi} and Keller, {Joseph Jordan} and Bai, {Chyi Huey}",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s00384-018-3117-4",
language = "English",
volume = "33",
pages = "1437--1444",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Increased risk of periodontitis among patients with Crohn’s disease

T2 - a population-based matched-cohort study

AU - Chi, Ying Chen

AU - Chen, Jiunn Liang

AU - Wang, Li Hsuan

AU - Chang, Koyin

AU - Wu, Chen Long

AU - Lin, Shu Yi

AU - Keller, Joseph Jordan

AU - Bai, Chyi Huey

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Periodontitis is a frequently cited extraintestinal manifestation of Crohn’s disease (CD). Despite a plethora of investigations and a recent meta-analysis linking CD and periodontitis, no study has estimated the risk of periodontitis among CD patients with respect to a comparison group nor has any investigation analyzed the effect of CD-specific medications on the risk of periodontitis. The present cohort study compared CD patients and matched subjects without a history of inflammatory bowel disease (IBD) to estimate the effect of CD and CD-specific pharmaceutical prescriptions on the risk of developing periodontitis by leveraging a population-based dataset in Taiwan. Methods: We sourced 6657 CD patients and 26,628 comparison subjects without a history of IBD from the Taiwan National Health Insurance Database. Cox proportional hazards regressions were used to estimate the risk of subsequent periodontitis by CD status and pharmaceutical prescription during the follow-up period. Results: After adjusting for socioeconomic status (SES), urbanicity, selected medical co-morbidities, and CD-specific pharmaceutical prescriptions, the hazard ratio (HR) for subsequent periodontitis among patients with CD was 1.36 (95% CI = 1.25–1.48) that of comparison subjects. There was not a significant difference in risk between genders or across ages. Steroids (95% CI = 0.66–0.77) appeared to confer a protective effect and Aspirin, Plavix, and Licodin were marginally protective (95% CI = 0.76–0.95). Conclusion: This is the first study to report an increased HR for subsequent periodontitis among CD patients when compared to matched comparison subjects without IBD. The protective effect of some pharmaceuticals may suggest that treatment of CD protects against periodontitis.

AB - Background: Periodontitis is a frequently cited extraintestinal manifestation of Crohn’s disease (CD). Despite a plethora of investigations and a recent meta-analysis linking CD and periodontitis, no study has estimated the risk of periodontitis among CD patients with respect to a comparison group nor has any investigation analyzed the effect of CD-specific medications on the risk of periodontitis. The present cohort study compared CD patients and matched subjects without a history of inflammatory bowel disease (IBD) to estimate the effect of CD and CD-specific pharmaceutical prescriptions on the risk of developing periodontitis by leveraging a population-based dataset in Taiwan. Methods: We sourced 6657 CD patients and 26,628 comparison subjects without a history of IBD from the Taiwan National Health Insurance Database. Cox proportional hazards regressions were used to estimate the risk of subsequent periodontitis by CD status and pharmaceutical prescription during the follow-up period. Results: After adjusting for socioeconomic status (SES), urbanicity, selected medical co-morbidities, and CD-specific pharmaceutical prescriptions, the hazard ratio (HR) for subsequent periodontitis among patients with CD was 1.36 (95% CI = 1.25–1.48) that of comparison subjects. There was not a significant difference in risk between genders or across ages. Steroids (95% CI = 0.66–0.77) appeared to confer a protective effect and Aspirin, Plavix, and Licodin were marginally protective (95% CI = 0.76–0.95). Conclusion: This is the first study to report an increased HR for subsequent periodontitis among CD patients when compared to matched comparison subjects without IBD. The protective effect of some pharmaceuticals may suggest that treatment of CD protects against periodontitis.

KW - Crohn’s disease

KW - Epidemiology

KW - Periodontitis

UR - http://www.scopus.com/inward/record.url?scp=85049770973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049770973&partnerID=8YFLogxK

U2 - 10.1007/s00384-018-3117-4

DO - 10.1007/s00384-018-3117-4

M3 - Article

VL - 33

SP - 1437

EP - 1444

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 10

ER -